Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission

Daniel J. Weisdorf, Heather R. Millard, Mary M. Horowitz, Parvinder S. Hyare, Richard Champlin, Vincent Ho, Marco Mielcarek, Andrew Rezvani, Keith Stockerl-Goldstein, Hanna J. Khoury, Marcos De Lima, Wael Saber, Brenda Sandmaier, Mei Jie Zhang, Mary Eapen

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

BACKGROUND: Patients with acute myeloid leukemia (AML) without complete remission (CR) or in first relapse (Rel1) can have extended leukemia control and survival after allogeneic hematopoietic cell transplantation (HCT). For patients in Rel1 or primary induction failure (PIF), transplantation versus treatment to achieve a second CR (CR2) and subsequent HCT might yield similar outcomes, but available comparative data are scarce. METHODS: Survival was analyzed in 4682 HCT recipients according to disease status: PIF (N = 1440), Rel1 (failing ≥1 reinduction; N = 1256), and CR2 (N = 1986). RESULTS: Patient, disease, and transplantation characteristics were similar, except that patients in CR2 more often had performance scores of 90% to 100%, de novo AML, and longer CR1 duration. Adverse cytogenetics were more common in patients who experienced PIF. The 5-year survival rate adjusted for performance score, cytogenetic risk, and donor type for CR2 was 39% (95% confidence interval [CI], 37%-41%) compared with 18% (95% CI, 16%-20%) for HCT in Rel1 and 21% (95% CI, 19%-23%) in PIF (P <.0001). CONCLUSIONS: Although survival is superior for patients who undergo HCT in CR2, transplantation for selected patients in Rel1 or PIF may still be valuable. These data can guide decision making about additional salvage therapy versus prompt HCT for patients not in CR, but they also highlight that AML is intrinsically more treatable in patients who have favorable-risk cytogenetics, those with longer CR1 duration, and younger patients with better performance status. Cancer 2017;123:2025–2034.

Original languageEnglish
Pages (from-to)2025-2034
Number of pages10
JournalCancer
Volume123
Issue number11
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Keywords

  • acute myeloid leukemia
  • allogeneic transplantation
  • complete remission
  • primary induction failure
  • relapse

Fingerprint Dive into the research topics of 'Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission'. Together they form a unique fingerprint.

  • Cite this

    Weisdorf, D. J., Millard, H. R., Horowitz, M. M., Hyare, P. S., Champlin, R., Ho, V., Mielcarek, M., Rezvani, A., Stockerl-Goldstein, K., Khoury, H. J., De Lima, M., Saber, W., Sandmaier, B., Zhang, M. J., & Eapen, M. (2017). Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer, 123(11), 2025-2034. https://doi.org/10.1002/cncr.30536